July 26, 2024 01:45 PM EDTUpdated July 29, 12:14 PM

Updated: Bristol Myers restarts radiopharmaceutical Phase 3 trial

Kyle LaHucik

Senior Reporter

Bristol Myers Squibb has resumed recruitment for its lead radiopharmaceutical trial after an isotope shortage forced a pause earlier this year, chief medical officer Samit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Bristol Myers restarts radiopharmaceutical Phase 3 trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Up­dat­ed: Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Updated: Bristol Myers restarts radiopharmaceutical Phase 3 trial

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials